New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADXRadiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
0.63
0.04
−5.97%
After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.
Follow RADX
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 2 | 2 | +209.4% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 1.08 | 9.52 | (90.5) pt | ||||||
| EBT | — | — | — | — | — | — | — | (31) | (25) | (39) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (15,994.80) | (1,052.43) | (2,055.54) | +13,939.3 pt | ||||||
| Net income | — | — | — | — | — | — | — | (31) | (25) | (39) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.15 | 0.34 | 0.18 | +9.7% | |||||
| Earnings | — | — | — | — | — | — | — | (24.41) | (3.58) | (3.65) | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | (11.70) | (3.42) | (3.50) | n/m | ||||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.28 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | (11.70) | (3.14) | (3.50) | n/m | ||||||
| Book value | — | — | — | — | — | — | — | 13.93 | 4.00 | 1.48 | (67.4%) | ||||||
| Shares, m | — | — | — | — | — | — | — | 1 | 7 | 10 | +182.0% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.03 | 0.0 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (15) | (24) | (36) | n/m | |||||
| Capex | — | — | — | — | — | — | — | — | 2 | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | (15) | (22) | (36) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 3 | 16 | 2 | (22.9%) | |||||
| Net debt | — | — | — | — | — | — | — | (12) | (19) | (3) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 18 | 28 | 15 | (8.1%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | (48.10) | (79.84) | (31.7) pt | |||||
| ROIC | — | — | — | — | — | — | — | (336.13) | (173.45) | (195.15) | +141.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | (108.66) | (180.13) | (71.5) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 7 | 14 | 14 | +41.4% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.03 | 0.17 | 0.13 | +118.8% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2026 · fundamentals updated Nov 2, 2026
Radiopharm Theranostics Limited - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BCDA BioCardia, Inc. | $11.7M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −2.93% (below 0%: shrinking) | 100.00% | (54,966.67%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | +17.68% (above 0%: growing) | 0.00% | — | Compare |
| AEON AEON Biopharma, Inc. | $11.2M | — (loss-making) | — | — | n/m | −120.53% (below 0%: shrinking) | — | — | Compare |
| PBM Psyence Biomedical Ltd. | $10.9M | 0.1× | — | — | n/m | −1,628.07% (below 0%: shrinking) | — | — | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $10.6M | — | — | — | — | — | — | — | |
| HIND Vyome Holdings, Inc. | $10.2M | — (loss-making) | — (loss-making) | +67.63% (above 0%: growing) | n/m | +63.50% (above 0%: growing) | 46.21% | (1,760.52%) | Compare |
| LSTA Lisata Therapeutics, Inc. | $9.8M | — (loss-making) | — (loss-making) | — | n/m | −279.44% (below 0%: shrinking) | 100.00% | (3,080.00%) | Compare |
| BIVI BioVie Inc. | $9.8M | — (loss-making) | — | — | n/m | +3.92% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LEXX Lexaria Bioscience Corp. | $9.5M | — (loss-making) | — (loss-making) | — | n/m | +53.90% (above 0%: growing) | 100.00% | (7,259.50%) | Compare |
| Median of peers | $10.5M | — | — | — | — | +0.49% | 73.11% | (3,080.00%) |
Radiopharm Theranostics Limited - Sponsored ADR (RADX) Latest News
What happened
- Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases GlobeNewswire
- Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 GlobeNewswire
- Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- RADX: RAD101 Topline & FY:26 Cash Flows
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
- Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs Insider Monkey
- Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study MarketBeat
19 more headlines
- Radiopharm Theranostics Reports Business Update GlobeNewswire
- Edison Issues Report on Starpharma (SPL) TMX Newsfile
- Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- RADX: Fiscal 3Q:26 Cash Flow Report Zacks Small Cap Research
- Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference MarketBeat
- Radiopharm Theranostics Reports Business Update GlobeNewswire
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases GlobeNewswire
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. GlobeNewswire
- RADX: RAD 101 Phase IIb Interim Analysis Zacks Small Cap Research
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer GlobeNewswire
- Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial Proactive Investors
- Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks MarketBeat
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases GlobeNewswire
- AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) PR Newswire